Study Detail

Repurposing FDA-Approved Drugs for Treatment of 2019-nCoV-induced Disease

Repurposing FDA-Approved Drugs for Treatment of 2019-nCoV-induced Disease

Status: not available

Type: Pre-clinical

Funder: NIHR/UKRI

Sponsor: Queens University Belfast

CI: Professor Ultan Power

IRAS-Number: Pre-clinical

CPMS-ID: not available

Approval Date: 11 March 2020

Description:

Drug repurposing is defined as the application of known drugs to new indications. This approach is attractive, as repurposed drugs have already passed toxicity trials. Therefore, we aim to screen clinically approved drugs either as single or pair combinations for the therapeutic development of antiviral and anti-inflammatory agents to control and treat COVID-19 disease. We strongly anticipate the data generated will identify novel single or synergistic drug pairs, lead to detailed pre-clinical evaluation and provide the impetus for rapid progress to clinical trials or compassionate use in extreme cases.

Study URL:

https://www.qub.ac.uk/coronavirus/research/latest-research-updates/working-to-find-a-coronavirus-treatment/drug-repurposing-key-to-addressing-covid-19-pandemic/

Back to listing